Immusoft Corporation

Thanks @WIRED @emilylmullin for speaking with our CEO Sean Ainsworth about the first engineered B cell therapy dosed in human trials: 🧬🧬🧬 wired.com/story/b-cells-…

We’re excited to announce our presentation at @WORLDSymposia 2024 Conference, held in San Diego, February 4-9. WORLDSymposium is the largest international gathering of lysosomal disease researchers. Read the full release: businesswire.com/news/home/2024…

.@DDWJournal covers our recent first patient dosed using the world’s first engineered B cell therapy. 🧬🧬🧬 ddw-online.com/worlds-first-e…

.@TrialsArena covers our first patient dosed in #MPS1: clinicaltrialsarena.com/news/immusoft-…

A trial by Seattle-based Immusoft, a biotech company, said it is the first to genetically engineer B cells and test them in a patient, Wired reported Dec. 15. bit.ly/3TtmJH2

@jan_nolta @CIRMnews Thank you!

@CIRMnews @immusoft Congratulations to @immusoft! Very cool technology. 👏🏻👏🏻🎉

CIRM is proud to support @immusoft's groundbreaking B cell therapy trial for MPS I and other diseases. "Our goal is always to move the most promising research forward as fast as we can,” said Dr. Abla Creasey, VP of Therapeutics Development at CIRM. wired.com/story/b-cells-…

Thanks @Inside_PM for covering our first patient dosed news! insideprecisionmedicine.com/topics/transla…

@emilylmullin, from @WIRED, writes:  "@immusoft announced that its scientists have genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease. It’s the first time engineered B cells have been tested in a person." bit.ly/3RKOj1q

.@FierceBiotech covers our first patient dosed for the world’s first engineered B cell therapy. 🧬🧬🧬 fiercebiotech.com/biotech/first-…

Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge. wired.com/story/b-cells-…

Immusoft Begins Clinical Trial of Autologous B-Cell Therapy in Mucopolysaccharidosis Type I. ISP-001, which Immusoft developed using its Immune System Programming platform, aims to reprogram patients' B cells so they keep producing alpha-L-iduronidase. ow.ly/pCGK1055NEQ

Engineering B-cells: First in human trial in patient with mucopolysaccharidosis type I Ex vivo B-cell gene engineering to produce missing enzyme by @immusoft wired.com/story/b-cells-…

The Westcott family first invested in @immusoft in 2013 when the idea of genetically engineering B-cells (antibody) was just that…an idea. Ten years later, they have dosed their first patient. One day this technology could change millions of lives. We are proud to have played a small part. wired.com/story/b-cells-… CC: @VCBrags #biotech #bcells #VentureCapital

Immusoft Administers the First Engineered B Cell in a Human Clinical Trial dlvr.it/T09svn

Great companies, in great company! Honored for Aurion to share BioFuture Stage with @endpts @leileiwuu, Sean Ainsworth @Immusoft, Christine Silverstein @ExcisionBio, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.

At this year's @ASGCTherapy annual meeting, engineered B cells are shining 🤩 Beautiful abstracts from @PaulaUSC Matthew Porteus, Jennifer Adair, @JustinTaylorLab , @HPKiem , Richard James and David Rawlings, @immusoft and @bebiopharma

M&A #news ~@immusoft acquires exclusive, worldwide rights to @UMNews's #IP for #genome edited primary B Cells ~#BiminiHealthTech acquires exclusive license to #accellular dermal matrix product portfolio ~@Mindstrong sells #tech assets to @SonderMind

Excited to announce we’ve acquired the exclusive worldwide rights to IP for #genomeediting technology for primary B cells. 🧬🧬🧬 Read the full release: businesswire.com/news/home/2023…

Genome-editing of primary B cells is becoming increasingly important in this space. It’s exciting to be a scientific advisor to Immusoft, the leader in engineered B cells. @eqxfund @immusoft #proudinvestor businesswire.com/news/home/2023…